100 related articles for article (PubMed ID: 26978018)
1. [Matrix metalloproteinases 2 and 9, their endogenous regulators, and angiotensin-converting enzyme in cervical squamous cell carcinoma].
Timoshenko OS; Kugaevskaya EV; Gureeva TA; Zavalishina LE; Andreeva YY; Solovуeva NI
Arkh Patol; 2015; 77(5):31-35. PubMed ID: 26978018
[TBL] [Abstract][Full Text] [Related]
2. [Key enzymes of degradation and angiogenesis as a factors of tumor progression in squamous cell carcinoma of the cervix].
Solov'eva NI; Timoshenko OS; Kugaevskaia EV; Andreeva IuIu; Zavalishina LE
Bioorg Khim; 2014; 40(6):743-51. PubMed ID: 25895371
[TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas.
Siddique K; Yanamandra N; Gujrati M; Dinh D; Rao JS; Olivero W
Int J Oncol; 2003 Feb; 22(2):289-94. PubMed ID: 12527924
[TBL] [Abstract][Full Text] [Related]
4. [Matrix metalloproteinases (MMP)--MMP-1,-2,-9 and its endogenous activity regulators in transformed by E7 oncogene HPV16 and HPV18 cervical carcinoma cell lines].
Ryzhakova OS; Solov'eva NI
Biomed Khim; 2013; 59(5):530-40. PubMed ID: 24479343
[TBL] [Abstract][Full Text] [Related]
5. [Interstitial collagenase, gelatinases A and B and their endogenous inhibitors in squamous cell cervical carcinomas].
Ryzhakova OS; Zavalishina LÉ; Andreeva IuIu; Solov'eva NI
Biomed Khim; 2013; 59(1):55-64. PubMed ID: 23650722
[TBL] [Abstract][Full Text] [Related]
6. [Gelatinases A and B and their endogenous regulators in the corpus uteri in squamous cell cervical carcinoma].
Timoshenko OS; Gureeva TA; Kugaevskaya EV; Zavalishina LE; Andreeva YY; Solovyeva NI
Arkh Patol; 2018; 80(6):22-28. PubMed ID: 30585589
[TBL] [Abstract][Full Text] [Related]
7. [Membrane type 1 matrix metalloproteinase (MT1-MMP) and the regulators of its activity as invasive factors in squamous cell cervical carcinomas].
Timoshenko OS; Gureeva TA; Kugaevskaia EV; Solov'eva NI
Biomed Khim; 2014; 60(6):683-8. PubMed ID: 25552509
[TBL] [Abstract][Full Text] [Related]
8. [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix].
Zhou CY; Yao JF; Chen XD
Ai Zheng; 2002 Jul; 21(7):735-9. PubMed ID: 12479097
[TBL] [Abstract][Full Text] [Related]
9. Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Hedbrant A; Wijkander J; Seidal T; Delbro D; Erlandsson A
Tumour Biol; 2015 Nov; 36(11):8715-25. PubMed ID: 26050228
[TBL] [Abstract][Full Text] [Related]
10. [Matrix metalloproteinases and their endogenous regulators in squamous cervical carcinoma (review of the own data)].
Solovуeva NI; Timoshenko OS; Gureeva TA; Kugaevskaya EV
Biomed Khim; 2015; 61(6):694-704. PubMed ID: 26716740
[TBL] [Abstract][Full Text] [Related]
11. [Tissue collagenase MMP-14 and endogenous regulators of its activity in the corpus uteri in squamous cell carcinoma of the cervix].
Timoshenko OS; Gureeva TA; Kugaevskaya EV; Zavalishina LE; Andreeva YY; Solovyeva NI
Arkh Patol; 2017; 79(6):36-42. PubMed ID: 29265076
[TBL] [Abstract][Full Text] [Related]
12. Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines.
Iwasaki M; Nishikawa A; Fujimoto T; Akutagawa N; Manase K; Endo T; Yoshida K; Maekawa R; Yoshioka T; Kudo R
Gynecol Oncol; 2002 Apr; 85(1):103-7. PubMed ID: 11925127
[TBL] [Abstract][Full Text] [Related]
13. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
[TBL] [Abstract][Full Text] [Related]
14. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
15. [Expression of matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in papillary thyroid cancer: an association with the clinical, morphological and ultrastructural characteristics of a tumor].
Delektorskaia VV; Smirnova EA; Ponomareva MV; Pavlova TV; Pavlov IA
Arkh Patol; 2010; 72(4):3-6. PubMed ID: 21086628
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: A systematic review and meta-analysis of case-control trials.
Liu HY; Gu WJ; Wang CZ; Ji XJ; Mu YM
Medicine (Baltimore); 2016 Jun; 95(24):e3904. PubMed ID: 27310993
[TBL] [Abstract][Full Text] [Related]
17. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
18. Stromal cells play a role in cervical cancer progression mediated by MMP-2 protein.
Fernandes T; de Angelo-Andrade LA; Morais SS; Pinto GA; Chagas CA; Maria-Engler SS; Zeferino LC
Eur J Gynaecol Oncol; 2008; 29(4):341-4. PubMed ID: 18714566
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression.
O'Grady A; Dunne C; O'Kelly P; Murphy GM; Leader M; Kay E
Histopathology; 2007 Dec; 51(6):793-804. PubMed ID: 18042068
[TBL] [Abstract][Full Text] [Related]
20. [Expression of MMPPs and TIMP and invasiveness in pituitary adenomas].
Wang J; Liu YS
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):647-50. PubMed ID: 16114548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
